x

Posted 30 January, 2024

Comera Life Sciences Holdings, Inc. appointed new CEO

CEO Change detected for ticker OTC:CMRA in a 8-K filed on 30 January, 2024.


  On January 29, 2024, the Company terminated the employment of Jeff Hackman, President, Chief Executive Officer and Director, Michael Campbell, Executive Vice President and Chief Financial Officer, and Robert Mahoney, Chief Scientific Officer effective January 31, 2024. In accordance with the terms of his employment letter agreement, Mr. Hackman resigned as a director of the Company and its subsidiaries and from all other positions with the Company and its affiliates effective upon the termination of his employment on January 31, 2024.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Comera Life Sciences Holdings, Inc.
Health Care/Life Sciences • Biotechnology
Comera Life Sciences Holdings, Inc. engages in developing medicines. It applies a deep knowledge of formulation science and technology to transform essential biologic medicines. The firm's approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen. The company was founded on January 31, 2022 and is headquartered in Woburn, MA.
Market Cap
$1.84M
View Company Details
Comera Life Sciences Holdings, Inc. by TradingView
Relevant filing section
Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain

Officers; Compensatory Arrangements of Certain Officers. 


On January 29, 2024, William Wexler resigned from the Company's board of directors effective immediately. As of the time of his resignation, Mr. Wexler did not serve on any committees of the board of directors and his resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices.

On January 29, 2024, the Company terminated the employment of Jeff Hackman, President, Chief Executive Officer and Director, Michael Campbell, Executive Vice President and Chief Financial Officer, and Robert Mahoney, Chief Scientific Officer effective January 31, 2024. In accordance with the terms of his employment letter agreement, Mr. Hackman resigned as a director of the Company and its subsidiaries and from all other positions with the Company and its affiliates effective upon the termination of his employment on January 31, 2024. Mr. 


Hackman did not serve on any committees of the board of directors and his resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices.

On January 30, 2024, the Company engaged Mr. Campbell as a consultant and appointed him to serve as the Company's Chief Executive Officer and Chief Financial Officer effective immediately following the termination of his employment on January 31, 2024. Accordingly, Mr. Campbell will serve as the Company's principal executive officer, principal financial officer and principal accounting officer effective immediately following the termination of his employment on January 31, 2024. Mr. Campbell's biographical information is incorporated by reference to the Company's definitive proxy statement filed with the SEC on August 11, 2023. Pursuant to the terms of his consulting arrangement, Mr. Campbell will be paid at a rate of $2,400 per day and his consulting engagement can be terminated by the Company at any time and for any reason.